Phase 1 SOLID TUMOR HEMATOLOGY

Size: px
Start display at page:

Download "Phase 1 SOLID TUMOR HEMATOLOGY"

Transcription

1 FOR MORE INFORMATION OR TO REFER A PATIENT TO ANY OF OUR CLINICAL TRIALS PLEASE CONTACT NICOLE GIVEN, BS, OHC RESEARCH DEPARTMENT AT , EXT Phase 1 SOLID TUMOR BRE- 261: GO29831 (BAM Only) GI- 219: BBI (BAM Only) BBI608 provided REFMAL- 381: ABI ST- 001 (BAM Only) Nivolumab, Abraxane provided REFMAL- 404: TGR (BAM Only) TGR provided A, Randomized, Two- Arm Study Evaluating the Safety and Pharmacokinetics of MPDL328A (Anti- PD- L1 Antibody) in Combination with Trastuzumab Emtansine or Trastuzumab and Pertuzumab in Patients with HER2- Positive Breast Cancer A Clinical Study of BBI608 in Combination with Standard Chemotherapies in Adult Patients with Advanced Gastrointestinal Cancer Phase 1, Open- Label, Multi- Center, Safety Study of Nivolumab (BMS ) in Combination with Nab- Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab- Paclitaxel/Carboplatin in Stage IIIB/IV Non- Small Cell Lung Cancer or Nab- Paclitaxel in Recurrent Metastatic Breast Cancer A Study Evaluating the Safety and Efficacy of TGR 1202 Alone and in Combination with Either Nab- Paclitaxel + Gemcitabine or with FOLFOX in Patients with Select Relapsed or Refractory Solid Tumors HEMATOLOGY BMT- 10: INCB (pending 1 st Qtr) INCB provided MM- 56: CFZ013 (KWD Only) Carfilzomib provided A Randomized, Parallel- Cohort Study of INCB in Combination with Corticosteroids for the Treatment of Grade II- IV Acute Graft- Versus- Host Disease Study of Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma Page 1 of 19

2 Molecular Profiling PRO- 02: ML28897 a Erlotinib, Vismodegib, Pertuzumab, Trastuzumab, and Vemurafenib provided MY PATHWAY: An Open- Label A Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents FGFR PRO- 11: CBGJ398XUS04 BGJ398 provided Modular Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 6 BGJ398 for Patients with Tumors with FGFR Genetic Alterations ALK & ROS1 PRO- 12: CLDK378AUS23 (pending) LDK378 provided Modular Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 7 Ceritinib (LDK378) for Patients Whose Tumors have Aberrations in ALK or ROS1 Biliary Tract METASTATIC, FIRST- LINE GI- 234: I3O- MC- JSBF (pending 2 nd Qtr) Ramucirumab/placebo and merestinib/ placebo provided Randomized, Double- Blind, Phase 2 Study or Ramucirumab or Merestinib or Placebo plus Gemcitabine and Cisplatin as First- Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer Page 2 of 19

3 Bladder Clinical Trials METASTATIC, AT LEAST SECOND- LINE GU- 118: D2615C00001 (ON HOLD) AZD4547 and MEDI4736 provided An Open- Label, Non- Randomized, Multi- Drug, Biomarker- Directed, Multi- Center, Multi- Arm Study in Patients with Muscle Invasive Bladder Cancer (MIBC) who have Progressed on Prior Treatment (BISCAY) Breast Clinical Trials STAGE I TO IIIA, ADJUVANT OR NEO- ADJUVANT BRE- 270: SPI- GCF- 301/501 (pending 3 rd qtr) I Supportive Care SPI provided RAnDomized Trial of SPI Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide (TC) (ADVANCE- 1) STAGE IIB- III, TNBC BRE- 273: FRV- 002 (pending 3 rd qtr) A FRα and GM- CSF provided AR+, TNBC OR ER+ HER2 NORMAL BRE- 274: INO- VT CL- 006 (pending 2 nd Qtr) VT- 464 provided METASTATIC, FIRST- LINE, HER2+ BRE- 261: GO29831 (BAM only) A Randomized Controlled Multicenter A Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination with Folate Receptor Alpha Peptides with GM- CSF in Patients with Triple Negative Breast Cancer A Phase 1/2 Open- Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT- 464 in Patients with Advanced Breast Cancer A, Randomized, Two- Arm Study Evaluating the Safety and Pharmacokinetics of MPDL328A (Anti- PD- L1 Antibody) in Combination with Trastuzumab Emtansine or Trastuzumab and Pertuzumab in Patients with HER2- Positive Breast Cancer Page 3 of 19

4 METASTATIC, FIRST- LINE, TNBC BRE- 231: CDX CDX- 011 provided BRE- 258: WO29522 I METASTATIC, SECOND- LINE BRE- 261: GO29831 (BAM only) METASTATIC, SECOND- LINE, HER2+ BRE- 240: 9785CL a Enzalutamide provided METASTATIC, SECOND- LINE, TNBC BRE- 231: CDX CDX- 011 provided METASTATIC, THIRD- LINE, HER2+ BRE- 240: 9785CL a Enzalutamide provided A Randomized Multicenter Pivotal Study of CDX- 011 (CR011- vcmmae) in Patients with Metastatic, GPNMB Over- Expressing, Triple- Negative Breast Cancer (The METRIC Study) A I, Multicenter, Randomized Placebo- Controlled Study of MPDL3280A (Anti- PD- L1 Antibody) in Combination with Nab- Paclitaxel Compared with Placebo with Nab- Paclitaxel for Patients with Previously Untreated Metastatic Triple Negative Breast Cancer A, Randomized, Two- Arm Study Evaluating the Safety and Pharmacokinetics of MPDL328A (Anti- PD- L1 Antibody) in Combination with Trastuzumab Emtansine or Trastuzumab and Pertuzumab in Patients with HER2- Positive Breast Cancer A Phase 2a, Multicenter, Open- Label Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ Metastatic or Locally Advanced Breast Cancer A Randomized Multicenter Pivotal Study of CDX- 011 (CR011- vcmmae) in Patients with Metastatic, GPNMB Over- Expressing, Triple- Negative Breast Cancer (The METRIC Study) A Phase 2a, Multicenter, Open- Label Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ Metastatic or Locally Advanced Breast Cancer Page 4 of 19

5 BRE- 249: MM MM- 302 provided BRE- 261: GO29831 (BAM Only) METASTATIC, THIRD- LINE, TNBC BRE- 231: CDX CDX- 011 provided METASTATIC, REFRACTORY, HER2+ BRE- 240: 9785CL a Enzalutamide provided BRE- 249: MM MM- 302 provided BRE- 261: GO29831 (BAM only) A Randomized, Multicenter, Open Label Study of MM- 302 plus Trastuzumab vs. Chemotherapy of Physician s Choice plus Trastuzumab in Anthracycline Naïve Patients with Locally Advanced/Metastatic HER2- Positive Breast Cancer A, Randomized, Two- Arm Study Evaluating the Safety and Pharmacokinetics of MPDL328A (Anti- PD- L1 Antibody) in Combination with Trastuzumab Emtansine or Trastuzumab and Pertuzumab in Patients with HER2- Positive Breast Cancer A Randomized Multicenter Pivotal Study of CDX- 011 (CR011- vcmmae) in Patients with Metastatic, GPNMB Over- Expressing, Triple- Negative Breast Cancer (The METRIC Study) A Phase 2a, Multicenter, Open- Label Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ Metastatic or Locally Advanced Breast Cancer A Randomized, Multicenter, Open Label Study of MM- 302 plus Trastuzumab vs. Chemotherapy of Physician s Choice plus Trastuzumab in Anthracycline Naïve Patients with Locally Advanced/Metastatic HER2- Positive Breast Cancer A, Randomized, Two- Arm Study Evaluating the Safety and Pharmacokinetics of MPDL328A (Anti- PD- L1 Antibody) in Combination with Trastuzumab Emtansine or Trastuzumab and Pertuzumab in Patients with HER2- Positive Breast Cancer Page 5 of 19

6 METASTATIC, HR+ BRE- 252: LEE011E2301 I LEE011 provided BRE- 266: GO29689 GDC provided BRE- 267: CBYL719C2301 (pending 1 st Qtr) I Alpelisib/placebo provided A I Randomized, Double- Blind, Placebo- Controlled Study of LEE011 or Placebo in Combination with Tamoxifen and Goserelin for the Treatment of Premenopausal Women with Hormone Receptor Positive Advanced Breast Cancer who have Received No Prior Therapy for Advanced Disease (MONALEESA- 7) A, Open- Label Randomized Study of GDC versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy A I Randomized Double- Blind, Placebo- Controlled Study of Alpelisib in Combination with Fulvestrant versus Placebo plus Fulvestrant as First- or Second- Line Treatment for Post- Menopausal Women and Men with Hormone Receptor Positive, HER2- Negative, Advanced Breast Cancer Previously Treated with Endocrine Therapy Cholangio Clinical Trials GI- 219: BBI (BAM Only) BBI608 provided A Clinical Study of BBI608 in Combination with Standard Chemotherapies in Adult Patients with Advanced Gastrointestinal Cancer Colorectal/Rectal Clinical Trials METASTATIC, FIRST- LINE GI- 200: BP29262 RO and Bevacizumab provided A, Multicenter, Randomized, Double- Blind Study to Evaluate the Efficacy and Safety of RO plus FOLFOX versus Bevacizumab plus FOLFOX in Patients with Previously Untreated Metastatic Colorectal Cancer Page 6 of 19

7 REFMAL- 404: TGR TGR provided A Study Evaluating the Safety and Efficacy of TGR 1202 Alone and in Combination with Either Nab- Paclitaxel + Gemcitabine or with FOLFOX in Patients with Select Relapsed or Refractory Solid Tumors METASTATIC, SECOND- LINE GI- 219: BBI (BAM Only) BBI608 provided A Clinical Study of BBI608 in Combination with Standard Chemotherapies in Adult Patients with Advanced Gastrointestinal Cancer REFMAL- 404: TGR TGR provided A Study Evaluating the Safety and Efficacy of TGR 1202 Alone and in Combination with Either Nab- Paclitaxel + Gemcitabine or with FOLFOX in Patients with Select Relapsed or Refractory Solid Tumors Esophageal/Gastric Clinical Trials METASTATIC GI- 219: BBI (BAM Only) BBI608 provided A Clinical Study of BBI608 in Combination with Standard Chemotherapies in Adult Patients with Advanced Gastrointestinal Cancer METASTATIC, FIRST- LINE, HER2- GI- 208: I4T- MC- JVCU I IMC- 1121B provided GI- 222: GS- US (pending 1 st Qtr) I GS provided A Randomized, Double- Blind, Placebo- Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First- line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL) A Phase 3 Randomized, Double- Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of GS Combined with mfolfox6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Page 7 of 19

8 METASTATIC, SECOND- LINE GI- 201 Abraxane and Paclitaxel provided REFMAL- 404: TGR TGR provided A Study of nab- Paclitaxel plus Ramucirumab for the Second- Line Treatment of Patients with Metastatic Gastroesophageal Cancer A Study Evaluating the Safety and Efficacy of TGR 1202 Alone and in Combination with Either Nab- Paclitaxel + Gemcitabine or with FOLFOX in Patients with Select Relapsed or Refractory Solid Tumors GIST Clinical Trials REFMAL- 404: TGR TGR provided A Study Evaluating the Safety and Efficacy of TGR 1202 Alone and in Combination with Either Nab- Paclitaxel + Gemcitabine or with FOLFOX in Patients with Select Relapsed or Refractory Solid Tumors Kidney Clinical Trials ADVANCED, SECOND- LINE GU- 127: CA (pending 1 st Qtr) Ib/IV Nivolumab provided REFRACTORY GU- 128: C31005 (pending 1 st Qtr) MLN0128 and MLN1117 provided A Phase 3b/4 Safety Trial of Nivolumab (BMS ) in Subjects with Advanced or Metastatic Renal Cell Carcinoma Who Have Progressed During or After Receiving Prior Anti- Angiogenic Therapy CheckMate 374: CHECKpoint pathway and nivolumab clinical Trial Evaluation 374 A Phase 2, Open- label Study to Evaluate the Efficacy and Safety of Single- Agent MLN0128 and Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced Clear- Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor- Targeted Therapy Page 8 of 19

9 Liver Clinical Trials GI- 219: BBI (BAM Only) BBI608 provided A Clinical Study of BBI608 in Combination with Standard Chemotherapies in Adult Patients with Advanced Gastrointestinal Cancer Lung Non Small Cell Clinical Trials ADJUVANT LUN- 305: D5164C00001 (pending 1 st Qtr) I AZD9291/placebo provided LUN- 308: GO29527 I A I, Double- blind, Randomized, Placebo- Controlled Multi- center, Study to Assess the Efficacy and Safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB- IIIA Non- Small Cell Lung Carcinoma, following Complete Tumor Resection With or Without Adjuvant Chemotherapy (ADAURA) A I, Open label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti- PDL1 Antibody) Compared with Standard of Care Following Adjuvant Cisplatin- based Chemotherapy in PDL- 1 Selected Patients with Completely Resected Stage IB- IIIA Non- Small Cell Lung Cancer STAGE IIIB/IV, FIRST- LINE REFMAL- 381: ABI ST- 001 (BAM Only) Nivolumab, Abraxane provided Phase 1, Open- Label, Multi- Center, Safety Study of Nivolumab (BMS ) in Combination with Nab- Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab- Paclitaxel/Carboplatin in Stage IIIB/IV Non- Small Cell Lung Cancer or Nab- Paclitaxel in Recurrent Metastatic Breast Cancer STAGE IIIB/IV, SECOND- LINE LUN- 326: CA (pending 3 rd qtr) IB/IV Nivolumab provided A Dose Frequency Optimization, IB/IV Trial of Nivolumab 3 mg/kg Every 2 Weeks vs Nivolumab 6 mg/kg Every 4 Weeks in Subjects with Previously Treated Advanced or Metastatic Non- Small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg Every 2 Weeks CheckMate 384: CHECKpoint Pathway and nivolumab clinical Trial Evaluation 384 Page 9 of 19

10 ADVANCED, SECOND- THROUGH FOURTH- LINE LUN- 214 BKM120 provided Trial or Erlotinib and BKM120 in Patients with Advanced Non- Small- Cell Lung Cancer Previously Sensitive to Erlotinib METASTATIC LUN- 319: CA (pending 1 st Qtr) Nivolumab provided Sustain a i Study of Nivolumab in Maintenance or as Monotherapy or in Combination with Standard of Care Therapies in Stage IV NSCLC Subjects METASTATIC, FIRST- LINE LUN- 263: ABI NSCL- 003 I Abraxane provided LUN- 298: GO29437 I LUN- 299: GO29537 I LUN- 317: CL (pending 1 st Qtr) I ASP8273, Erlotinib, Gefitinib provided A I, Randomized, Open- Label, Crossover, Multi- Center, Safety and Efficacy Study to Evaluate nab- Paclitaxel (Abraxane) as Maintenance Treatment After Induction with nab- Paclitaxel plus Carboplatin in Subjects with Squamous Cell Non- Small cell Lung Cancer (NSCLC) A I, Open- Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of MPDL3280A (Anti- PD- L1 Antibody) in Combination with Carboplatin + Paclitaxel or MPDL3280A in Combination with Carboplatin + nab- Paclitaxel Versus Carboplatin + Paclitaxel in Chemotherapy- Naïve Patients with Stage IV Squamous Non- Small Cell Lung Cancer A I, Multicenter, Randomized, Open- Label Study Evaluating the Efficacy and Safety of MPDL328A (Anti- PD- L1 Antibody) in Combination with Carboplatin + Nab- Paclitaxel for Chemotherapy- Naïve Patients With Stage IV Non- Squamous Non- Small Cell Lung Cancer An Open- Label, Randomized Phase 3 Efficacy Study of ASP8273 vs. Erlotinib or Gefitinib in First- Line Treatment of Patients with Stage IIIB/IV Non- small Cell Lung Cancer Tumors with EGFR Activating Mutations Page 10 of 19

11 METASTATIC, SECOND- LINE LUN- 288: I6A- MC- CBBE LY and Necitumumab provided LUN- 328: PPHM 1501 (pending 2 nd Qtr) Durvalumab, Bavituximab provided A Study of the Combination of LY and Necitumumab after First Line Treatment for Metastatic Squamous Non- Small Cell Carcinoma of the Lung An Open- Label, Randomized, Trial of Durvalumab (MEDI4736) with or without Bavituximab in Patients with Previously Treated Metastatic Non- Small Cell Lung Cancer METASTATIC, THIRD- LINE LUN- 284: I3Y- MC- JPBK I LY provided LUN- 283: D4191C0004 I MEDI4736 and Tremelimumab provided METASTATIC, FIRST- LINE LUN- 299: GO29537 I Lung Small Cell Clinical Trials FIRST- LINE LUN- 244: 59R5-003 OMP- 59R5 provided A Randomized Phase 3 Study of LY versus Erlotinib in Patients with Stage IV NSCLC with a Detectable KRAS Mutation who Have Progressed after Platinum- Based Chemotherapy A I, Open label, Randomized, Multi- Center, International Study of MEDI4736, versus Standard of Care in Patients with Locally Advanced or Metastatic Non- Small Cell Lung Cancer (Stage IIIB- IV) Who Have Received at Least Two Prior Systemic Treatment A I, Multicenter, Randomized, Open- Label Study Evaluating the Efficacy and Safety of MPDL3280A (Anti- PD- L1 Antibody) in Combination with Carboplatin + Nab- Paclitaxel for Chemotherapy- Naïve Patients with Stage IV Non- Squamous Non- Small Cell Lung Cancer A Phase 1b/2 Study of OMP- 59R5 in Combination with Etoposide and Cisplatin in Subjects with Untreated Extensive Stage Small Cell Lung Cancer also now known as PINNACLE Page 11 of 19

12 RELAPSED/REFRACTORY LUN- 286: ALDOXORUBICIN- P2- SCLC- 01 b Aldoxorubicin and Topotecan provided EXTENSIVE- STAGE LUN- 318: CA (pending 2 nd qtr) I Nivolumab, ipilimumab, placebo provided LUN- 327: I4D- MC- JTJH (pending 2 nd Qtr) LY provided A Multicenter, Randomized, Open- Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects with Metastatic Small Cell Lung Cancer who Either Relapsed or Were Refractory to Prior Chemotherapy A Randomized, Multicenter, Double Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo in Subjects with Extensive- Disease Stage Small Cell lung cancer (SCLC) after Completion of Platinum based First Line Chemotherapy A Phase 2 Study of LY in Patients with Extensive Stage Disease Small Cell Lung Cancer Neuroendocrine GI- 195 Carfilzomib provided A Study of Carfilzomib for the Treatment of Patients with Advanced Neuroendocrine Cancers Ovarian Clinical Trials FIRST- LINE GYN- 61: B (pending 2 nd Qtr) I Avelumab provided A Randomized, Open- Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab (MSB C) in Combination with and/or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer Page 12 of 19

13 THIRD- LINE GYN- 41: ET743- OVC I Doxil and Trabectedin provided A Randomized, Open- Label Study Comparing the Combination of Yondelis and Doxil/Caelyx with Doxil/Caelyx Monotherapy for the Treatment of Advanced/Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer UNRESECTABLE GYN- 52: PM1183- C (pending 2 nd Qtr) I PM01183 provided I Randomized Clinical Trial of Lurbinectedin (PM01183) versus Pegylated Liposomal Doxorubicin or Topotecan in Patients with Platinum- Resistant Ovarian Cancer (CORAIL Trial) Pancreas Clinical Trials ADJUVANT GI- 194: ABI PANC- 003 I Abraxane provided A Phase 3, Multicenter, Open- Label, Randomized Study of nab- Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma METASTATIC, FIRST- LINE GI- 220: ACE- ST- 004 Pazopanib/placebo provided GI- 231: MM (pending 2 nd qtr) Nal- IRI, 5FU, Leucovorin/levoleucovorin, Oxaliplatin, nab- Paclitaxel and Gemcitabine provided A Phase 2 Proof- of- Concept Study of ACP- 196 in Combination with nab- Paclitaxel/Gemcitabine in Subjects with Previously Untreated Metastatic Pancreatic Cancer A Randomized, Open- label Phase 2 Study of Nanoliposomal Irinotecan (nal- IRI)- containing Regimens versus nab- Paclitaxel plus Gemcitabine in Patients with Previously Untreated, Metastatic Pancreatic Adenocarcinoma Page 13 of 19

14 REFMAL- 404: TGR TGR provided A Study Evaluating the Safety and Efficacy of TGR 1202 Alone and in Combination with Either Nab- Paclitaxel + Gemcitabine or with FOLFOX in Patients with Select Relapsed or Refractory Solid Tumors METASTATIC; SECOND- LINE GI- 199: INCB (ON HOLD) I Capecitabine and Ruxolitinib provided GI- 219: BBI (BAM Only) BBI608 provided A Randomized, Double- Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First- Line Chemotherapy (The JANUS 2 Study) A Clinical Study of BBI608 in Combination with Standard Chemotherapies in Adult Patients with Advanced Gastrointestinal Cancer Prostate Clinical Trials METASTATIC, CASTRATION RESISTANT GU- 115: I6A- MC- CBBD LY provided A Randomized Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY in Men with Chemotherapy Naïve Metastatic Prostate Cancer Sarcoma ADVANCED/METASTATIC SARC- 03: I5B- MC- JGDJ I Olaratumab/placebo provided A Randomized, Double- Blind, Placebo- Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma Page 14 of 19

15 Urothelial LOCALLY ADVANCED/UNRESECTABLE/METASTATIC GU- 120: I4T- MC- JVDC I IMC- 1121B provided A Phase 3, Randomized, Double- Blind, Placebo- Controlled Study of Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Transitional Cell Carcinoma of the Urothelium who Progressed following Platinum- based Therapy Hematological Malignancies ACUTE MYELOID LEUKEMIA (AML) FIRST- LINE AML- 31: SGN33A- 005 (pending 2 nd Qtr) I SGN33A provided CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) FIRST- LINE CLL- 37: ACE- CL- 007 (pending 2 nd qtr) I ACP- 196, Obinutuzumab and Chlorambucil provided A Randomized, Double- Blind, Phase 3 Study of SGN- CD33A (vadastuximab talirine) or Placebo in Combination with azacitidine or decitabine in the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) who are Ineligible or Unfit for Treatment with Intensive Induction Chemotherapy A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination with Ibrutinib Compared to Ibrutinib Alone, in Patients with Previously Treated High- Risk Chronic Lymphocytic Leukemia (CLL) AT LEAST SECOND- LINE CLL- 35: UTX- IB- 301 I Ublituximab provided A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination with Ibrutinib Compared to Ibrutinib Alone, in Patients with Previously Treated High- Risk Chronic Lymphocytic Leukemia (CLL) Page 15 of 19

16 RELAPSED/REFRACTORY LYM- 89 (GS- US ) GS provided A Phase 2 Open Label, Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS in Patients with Relapsed or Refractory Hematologic Malignancies CHRONIC MYELOGENOUS LEUKEMIA (CML) CML- 18: CA V BMS MANTLE CELL LEUKEMIA (MCL) LYM- 117: ACE- LY- 106 (pending 2 nd Qtr) B ACP- 196 provided An Open Label, Randomized V Study of Dasatinib vs Imatinib in the Treatment of Subjects with Chronic Phase Chronic Myeloid Leukemia who have not Optimally Responded to 3 Months of Therapy with 400 mg Imatinib A Phase 1b, Multicenter, Open- label Study of ACP- 196 in Combination with Bendamustine and Rituximab (BR) in Subjects with Mantle Cell Lymphoma MULTIPLE MYELOMA FIRST- LINE E1A11 I Carfilzomib provided MM- 56: CFZ013 (KWD only) Carfilzomib provided RELAPSED/REFRACTORY MM- 42: MLN9708 /II MLN9708 provided Randomized I Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE) Study of Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma Open- Label Study to Determine the Feasibility of MLN9708 as Maintenance after Allogeneic Stem Cell Transplant for Multiple Myeloma, Followed by an Expansion Phase at the Maximum- Tolerated Dose (MTD) Page 16 of 19

17 MM- 56: CFZ013 (KWD Only) Carfilzomib provided THIRD- LINE AND BEYOND MM- 69: KCP (pending 2 nd qtr) Selinexor (KPT- 330)/placebo provided SMOULDERING MM- 60: SMM2001 Daratumumab provided Study of Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma A Phase 2, Randomized, Double- Blind, Placebo- Controlled Multicenter Study of Selinexor (KPT- 330), Carfilzomib, and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Previously Treated with a Proteasome Inhibitor and an Immunomodulatory Drug A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma MYELOPROLIFERATIVE NEOPLASMS MPN- 07: MYF2001 (pending 1 st qtr) Imetelstat provided A Randomized, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat (GRN163L) in Subjects with Intermediate- 2 or Hihg- Risk Myelofibrosis (MF) Previously Treated with Janus Kinase (JAK) Inhibitor MPN- 08: WO29806 (KWD Only) /II GDC provided A B/II, Randomized, Double- Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Vismodegib in Combination with Ruxolitinib versus Placebo and Ruxolitinib in Intermediate to High Risk Myelofibrosis Page 17 of 19

18 NON- HODGKIN S LYMPHOMA- FOLLICULAR FIRST- LINE LYM- 104: GO27878 /II ABT- 199, GA101 and Rituximab provided A B/II, Open- Label Study Evaluating the Safety and Pharmacokinetics of GDC (ABT- 199) in Combination with Rituximab or Obinutuzumab plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with B- Cell Non- Hodgkin s Lymphoma (NHL) and DLBCL LYM- 115: BGB GA101 (pending 2 nd Qtr) A Phaese Ib Study to Assess Safety, Tolerability and Antitumor Activity of the Combination of BGB with Obinutuzumab in Subjects with B- Cell Lymphoid Malignancies BGB provided RELAPSED/REFRACTORY LYM- 82: GO27834 DCDS4501A, DCDT2980S and GA101 provided LYM- 106: CC NHL- 007 I Lenalidomide/placebo provided LYM- 110: MDV (pending 1 st Qtr) MDV9300 provided TRANSPLANT BMT- 08: ACT (pending 3 rd qtr) Ponesimod provided A Randomized, Non- Comparative, Open- label, Multicenter, Trial Evaluation the Safety and Activity of Pinatuzumab Vedotin (DCDT2980S) in Combination with Rituximab and a Non- Randomized /II Evaluation of Polatuzumab Vedotin in Combination with Obinutuzumab in Patients with Relapsed or Refractory B- Cell Non- Hodgkin s Lymphoma A Phase 3, Double- Blind Randomized Study to Compare the Efficacy and Safety of Rituximab plus Lenalidomide (CC- 5013) versus Rituximab plus Placebo in Subjects with Relapsed/Refractory Indolent Lymphoma An International, Phase 2, Open- Label, Efficacy and Safety Study of MDV9300 in Patients With an Incomplete Response Following Salvage Therapy or Autologous Stem Cell Transplantation for Relapsed or Refractory CD20+ Diffuse Large B- Cell Lymphoma A Phase 2, Open Label, Single- Arm, Intra- patient Dose- Escalation Study with Ponesimod in Patients with Symptomatic Moderate or Severe Chronic GVHD Inadequately Responding to First or Second Line Therapy Page 18 of 19

19 BMT- 10: INCB (pending 1 st qtr) INCB provided BMT CTN 07LT (KWD only) I Lenalidomide BMT CTN 1101 (KWD only) I No drug provided BMT CTN 1205 (KWD only) No drug provided CIBMTR 10- CBA (KWD only) Observational No drug provided NMDP Research Repository (KWD only) Observational No drug provided A Randomized, Parallel- Cohort Study of INCB in Combination with Corticosteriods for the Treatment of Grade II- IV Acute Graft- Versus- Host Disease Continued, Long- Term Follow- Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol A Multi- Center, I, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (ducb) versus HLA- Haploidentical Related Bone Marrow (haplo- BM) for Patients with Hematologic Malignancies Easy- to- Read Informed Consent (ETRIC) for Hematopoietic Cell Transplantation Clinical Trials A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications Allogenic Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries/Hematopietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries Page 19 of 19

Phase 1 HEMATOLOGY. GI- 219: BBI (pending 1 st Qtr) Phase Ib Therapeutic BBI608 provided

Phase 1 HEMATOLOGY. GI- 219: BBI (pending 1 st Qtr) Phase Ib Therapeutic BBI608 provided FOR MORE INFORMATION OR TO REFER A PATIENT TO ANY OF OUR CLINICAL TRIALS, PLEASE CONTACT NICOLE GIVEN, BS, OHC RESEARCH DEPARTMENT AT 1-800- 710-4674 Phase 1 GI- 219: BBI608-246 (pending 1 st Qtr) Phase

More information

Phase 1 HEMATOLOGY METASTATIC, REFRACTORY, HER2+, BREAST. REFMAL 381 (Phase 1 open at BAM only) Phase I Therapeutic Nivolumab and abraxane provided

Phase 1 HEMATOLOGY METASTATIC, REFRACTORY, HER2+, BREAST. REFMAL 381 (Phase 1 open at BAM only) Phase I Therapeutic Nivolumab and abraxane provided FOR MORE INFORMATION OR TO REFER A PATIENT TO ANY OF OUR CLINICAL TRIALS PLEASE CONTACT NICOLE GIVEN, BS, OHC RESEARCH DEPARTEMENT AT 1-800- 710-4674 Phase 1 REFMAL 381 (Phase 1 open at BAM only) Phase

More information

Molecular Profiling METASTATIC, REFRACTORY, HER2+, BREAST PHASE 1, METASTATIC, RELAPSED/REFRACTORY, PROSTATE OVARIAN

Molecular Profiling METASTATIC, REFRACTORY, HER2+, BREAST PHASE 1, METASTATIC, RELAPSED/REFRACTORY, PROSTATE OVARIAN FOR MORE INFORMATION OR TO REFER A PATIENT TO ANY OF OUR CLINICAL TRIALS PLEASE CONTACT NICOLE GIVEN, BS, OHC RESEARCH DEPARTEMTN AT 513-751- 2273, EXT 27110 Phase 1 REFMAL 381 (Phase 1 open at BAM only)

More information

CLINICAL TRIALS ACC. Jul 2016

CLINICAL TRIALS ACC. Jul 2016 CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

More information

National Cancer Drugs Fund List - Approved

National Cancer Drugs Fund List - Approved National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer

More information

Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona

Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Solid Tumor: USON 15180 / A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab

More information

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list. February 2013 London Cancer New s Group (LCNDG) Work Plan for the London Cancer s Fund London Cancer s Fund List This Cancer s Fund (CDF) list of medicines and s is in two parts. 1. The standard list of

More information

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on

More information

6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017

6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/

More information

Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy

Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal

More information

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin

More information

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG

More information

University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan

University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan University of Groningen Health economics of targeted therapies Mihajlovic, Jovan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please

More information

MEDICAL PRIOR AUTHORIZATION

MEDICAL PRIOR AUTHORIZATION MEDICAL PRIOR AUTHORIZATION TAXOTERE (docetaxel) DOCEFREZ(docetaxel) docetaxel (generic) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered

More information

Date of HRA. Date Site Invited. Date Site Selected. Approval. Recruited. Date

Date of HRA. Date Site Invited. Date Site Selected. Approval. Recruited. Date 14/LO/0259 134883 RE-AKT: A randomised Phase II study of enzalutamide (MDV3100) in combination with AZD5363 in s with Metastatic Castration - Resistant Prostate Cancer Yes 08/01/2018 01/07/2016 01/07/2017

More information

Cancer drug approvals for paediatric indications (n=43)

Cancer drug approvals for paediatric indications (n=43) Appendix: Supplementary material [posted as supplied by author] Figure A. Identification of cohort of drugs Total number of antineoplastic and immunomodulating products approved by the EMA up to 31 December

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

Summary of Research and Writing Activities in Oncology

Summary of Research and Writing Activities in Oncology Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,

More information

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication. NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days

DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days Last updated Oct 17, 2018 Tumour Group Protocol Number Protocol Name on NCCP website Breast 200 Trastuzumab (IV) Monotherapy 21 days 201 Trastuzumab (IV) Monotherapy 7 days 202 DOCEtaxel Monotherapy 100mg/m2

More information

WASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles

WASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles 2 3 Mt. Vernon Port Angeles Bremerton Tacoma 5 5 Olympia Everett Edmonds Seattle 90 WASHINGTON 90 Spokane Cheney Pullman Longview 82 Tri-Cities Portland North Central Oregon City 5 84 OREGON Walla Walla

More information

Title Cancer Drug Phase Status

Title Cancer Drug Phase Status Clinical Trial Identifier Title Cancer Drug Phase Status NCT01164995 Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer Epithelial Ovarian Cancer

More information

I. Diagnosis of the cancer type in CUP

I. Diagnosis of the cancer type in CUP Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

OPEN TRIALS Accruals counted until 30-April Current Accrual

OPEN TRIALS Accruals counted until 30-April Current Accrual Disease group Breast OPEN TRIALS Trial Title Accrual Target IBCSG 48-14 POSITIVE IBCSG 50-14 OLYMPIA IBCSG 52-15 PALLAS SAKK 21/12 A study evaluating the pregnancy outcomes and safety of interrupting endocrine

More information

Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD

Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right

More information

All Studies by Indication

All Studies by Indication Therapeutic Area Protocol Number Drug/Device Phase Description Advanced malignancies 337 20101132 AMG 337 I " A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

Studies proceeding under pre HRA-Approval system (NHS Permission)

Studies proceeding under pre HRA-Approval system (NHS Permission) 15/NW/0004 162679 Studies proceeding under pre HRA-roval system (NHS Permission) A MULTI-CENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN MAINTENANCE TREATMENT FOR FIRST- LINE METASTATIC COLORECTAL

More information

CENTER FOR CLINICAL TRIALS St. Luke s Medical Center. Ongoing Clinical Trials CANCER INSTITUTE (36)

CENTER FOR CLINICAL TRIALS St. Luke s Medical Center. Ongoing Clinical Trials CANCER INSTITUTE (36) CENTER FOR CLINICAL TRIALS St. Luke s Medical Center Ongoing Clinical Trials CANCER INSTITUTE (36) BLOOD TITLE : A Randomized, Two By Two Arm, Multicenter, Open-Label Phase III Study Of BMS-354825 Administered

More information

Studienverzeichnis Medizinische Onkologie

Studienverzeichnis Medizinische Onkologie Studienverzeichnis Medizinische Onkologie Mammakarzinom, Gynäkologie 21/12 24/14 25/14 96/12 PALLAS I I Transdermal CR1447 (4-OH-testosterone) in endocrine responsive-her2 negative and triple negative-androgen

More information

Trial Trial Name Opening of the first site. Enzalutamide in combination with metformin vs. enzalutamide in patients with CRPC

Trial Trial Name Opening of the first site. Enzalutamide in combination with metformin vs. enzalutamide in patients with CRPC TRIALS TO BE ACTIVATED 2016/2017 Trial Trial Name Opening of the first site SAKK 41/13 SAKK 08/14 (IMPROVE) SAKK 16/14 SAKK 21/12 (Phase II part) GRAALL-2014 HD21 HOVON 103 SEL SAKK 30/10 IELSG-42 IELSG-43

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

CancerPACT Cancer Patients Alliance for Clinical Trials

CancerPACT Cancer Patients Alliance for Clinical Trials TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Ongoing Cancer Clinical Trials in the Salinas Valley Winter 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.2 3. Gastrointestinal

More information

BREAST. POLARIS: Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study

BREAST. POLARIS: Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study BREAST Advanced breast Cancer, metastatic breast cancer HER2 Negative Metastatic or Locally Advanced Unresectable BRCA Associated Breast Cancer Pfizer A5481082 NCT03280303 AbbVie M12-914 NCT02163694 POLARIS:

More information

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015 Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib

More information

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication. NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title

More information

CancerPACTS. Cancer Patients Alliance for Clinical Trials and Survivorship

CancerPACTS. Cancer Patients Alliance for Clinical Trials and Survivorship CancerPACTS Cancer Patients Alliance for Clinical Trials and Survivorship Listing of Cancer Clinical Trials Silicon Valley area of California Summer / Fall 2011 Solid Tumors 1. Breast. 2 2. Central Nervous

More information

Open Trials as of end of March 2016

Open Trials as of end of March 2016 EORTC 10085 PRO EORTC 10085 prospective part, Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG and NABCG inter study 30 30-Jun-2016 estelle.cassoly@sakk.ch IBCSG

More information

Azacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded

Azacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded Provincial Fundin Summary The interim Joint Oncoloy Dru Review (ijodr) was the precursor oncoloy dru review process prior to pcodr, which provided evidence-based recommendation for cancer treatments from

More information

Roche Investor Relations ASCO Planner 2016

Roche Investor Relations ASCO Planner 2016 Roche Investor Relations ASCO Planner 2016 Friday, June 3 Session Title: Pediatric Oncology I Date: Fri, June 3 Location: S504 Time: 3:00 PM - 6:00 PM Speaker Name: Veronique Minard-Colin 5:12 PM - 5:24

More information

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus

More information

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List NHLBI-MDS ECOG-A NCT02775383 Blood Disorders-Other The National Myelodysplastic Syndromes (MDS) Study PNH Registry M07-001 DRUG CO NCT01374360 Blood Disorders-Other PNH Registry A071102 ALLIANCE NCT02152982

More information

Our Clinical Trials. Oncology

Our Clinical Trials. Oncology Our Clinical Trials Oncology ANGIOGENESIS Trebananib (AMG 86) (angiopoietin inhibitor) ANTIBODY DRUG CONJUGATE, continued AMG 595 (anti-egfrviii) Trebananib With Paclitaxel and Trastuzumab or Capecitabine

More information

Date Site Confirmed By Sponsor. Non- Confirmation Status. HRA Approval Date. Date Site Confirmed

Date Site Confirmed By Sponsor. Non- Confirmation Status. HRA Approval Date. Date Site Confirmed Research Ethics Committee Reference Number Integrated Research Application System Number Submission Type Name of Trial First Patient Recruited? Date of First Patient Recruited Invited Selected Approval

More information

HRA Approval Date Site Date Site Sponsor. Non- Confirmation Status. Date Site Ready To Start

HRA Approval Date Site Date Site Sponsor. Non- Confirmation Status. Date Site Ready To Start Research Ethics Committee Reference Number Integrated Research Application System Number Submission Type Name of Trial Date of Receipt of Date of Valid Research Application First Patient Recruited? Date

More information

ASCO 2014 Highlights*

ASCO 2014 Highlights* ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s

More information

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List NHLBI-MDS ECOG-A NCT02775383 Blood Disorders-Other The National Myelodysplastic Syndromes (MDS) Study A221101 ALLIANCE NCT01781468 Brain A Phase III Randomized, Double-Blind Placebo Controlled Study of

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

Target date to recruit patients agreed? Target range minimum. Target range maximum

Target date to recruit patients agreed? Target range minimum. Target range maximum No REC Reference IRAS No Title Target number of patients agreed? Target range minimum Target range maximum Target date to recruit patients agreed? Planned Recruitment end date Total no of patients recruited

More information

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication. NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title

More information

PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN BY PRODUCT

PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN BY PRODUCT PAGE 175 PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN BY PRODUCT Summary of risk management plan for pembrolizumab This is a summary of the risk management plan (RMP) for pembrolizumab. The RMP details

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS

H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS Each of you should have 37 new cards: 7 orange cards for antimetabolites 11 white cards for miscellaneous drugs (2 DNA synthesis inhibitors, 1 enzyme,

More information

2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO

2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO 2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO Disclosures I received final support from ASCO Conquer Cancer foundation in two Merit Awards and one travel award I am on the speakers

More information

General Information, efficacy and safety data

General Information, efficacy and safety data Horizon Scanning in Oncology Horizon Scanning in Oncology 28 th Prioritization 3 rd quarter 2016 General Information, efficacy and safety data Nicole Grössmann Claudia Wild Please note: Within this document

More information

An D. Nguyen, MD Curriculum Vitae

An D. Nguyen, MD Curriculum Vitae OFFICE/ BUSINESS ADDRESS: Pacific Shores Medical Group 19582 Beach Blvd, Suite 212 Huntington Beach, CA 92648 Phone: (714) 252-9415 Fax: (714) 963-8407 ADDITIONAL OFFICE: 16300 Sand Canyon Avenue, Suite

More information

Etudes cliniques Service d Oncologie - Radiothérapie

Etudes cliniques Service d Oncologie - Radiothérapie Etudes cliniques Service d Oncologie - Radiothérapie Juillet 2016 SEIN-NEO ADJUVANT LORELEI -GO28888-1319 BCG : A phase II randomized, double-blind, parallel cohort study of neoadjuvant letrozole + GDC-0032

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 3: February 16, 2011 The Clinical Research E-News Now Open: RTOG 0631, Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis RTOG 1010, A Phase III Trial Evaluating

More information

Policy. Medical Policy Manual Approved Revised: Do Not Implement Until 3/2/19. Nivolumab (Intravenous)

Policy. Medical Policy Manual Approved Revised: Do Not Implement Until 3/2/19. Nivolumab (Intravenous) Nivolumab (Intravenous) NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3734-XX Opdivo 240

More information

2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용

2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용 2018 KSMO Immune Oncology Forum Immune checkpoint inhibitors in hematologic malignancies: evidences and perspectives 서울아산병원종양내과 홍정용 2018-07-18 Contents Introduction Immune checkpoint inhibtors in lymphomas

More information

Policy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab

Policy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab Medical Manual Approved Revised: Do Not Implement until 6/30/2019 Nivolumab NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB

More information

Development status of ONO-4538(nivolumab)1

Development status of ONO-4538(nivolumab)1 Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1

More information

An Introduction to Bone Marrow Transplant

An Introduction to Bone Marrow Transplant Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,

More information

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List A031501 ALLIANCE NCT03244384 Bladder Phase III Randomized Adjuvant study of MK-3475 (Pembrolizumab) in muscle invasive and locally advanced urothelial carcinoma (AMBASSADOR) Versus Observation NHLBI-MDS

More information

Min number of patients agreed to be recruited. Max number of patients agreed to be recruited

Min number of patients agreed to be recruited. Max number of patients agreed to be recruited be 12/SC/0139 98125 A PHASE III PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI- CENTRE, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 5: March 23, 2011 The Clinical Research E-News Now Open: CALGB 90802, Randomized Phase III trial comparing everolimus plus placebo versus everolimus plus bevacizumab for advanced renal

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting Media Release Basel, 8 May 2018 Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting New and updated pivotal combination

More information

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

Target date to recruit patients agreed? Target range minimum. Target range maximum. Agreed 1 1 Agreed 01/01/ /01/2016 Recruitment Finished

Target date to recruit patients agreed? Target range minimum. Target range maximum. Agreed 1 1 Agreed 01/01/ /01/2016 Recruitment Finished No REC Reference IRAS No Title Target number of patients agreed? Target range minimum Target range maximum Target date to recruit patients agreed? Planned Recruitment end date No of patients recruited

More information

Working Formulary January 2013 Oncology Chemotherapy Regimens

Working Formulary January 2013 Oncology Chemotherapy Regimens Working Formulary January 2013 Oncology Chemotherapy Regimens In the currently changing commissioning landscape, this document is intended to represent the up to date list of non clinical trial chemotherapy

More information

R&D Conference Call. CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu.

R&D Conference Call. CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu. R&D Conference Call CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu July 4, 2016 Forward-Looking Statements This presentation may include forward-looking

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 4: March 2, 2011 The Clinical Research E-News Now Open: E1608, A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients with Advanced Melanoma E2208, Randomized Phase II Study of

More information

a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation

a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation This resource has been developed to help guide you regarding the appropriate timing and conditions for a referral

More information

Checkpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health

Checkpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells

More information

Development status of ONO-4538(nivolumab)1

Development status of ONO-4538(nivolumab)1 Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1

More information

What s a Transplant? What s not?

What s a Transplant? What s not? What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting Investor Update Basel, 8 May 2018 Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting New and updated pivotal

More information

Media Release. Roche highlights personalised medicines and cancer immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

Media Release. Roche highlights personalised medicines and cancer immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting Media Release Basel, 3 May 2016 Roche highlights personalised medicines and cancer immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 19 Roche medicines are included in

More information

SCIENTIFIC PROGRAM. ASCO Direct 15CME HOURS. SCfHS ACCREDITED FOR. Current Update Sponsored by:

SCIENTIFIC PROGRAM. ASCO Direct 15CME HOURS. SCfHS ACCREDITED FOR. Current Update Sponsored by: ASCO Direct Current Update 2017 24-25 November 2017 Crowne Plaza Hotel, Jeddah, KSA SCIENTIFIC PROGRAM Organized by: SCfHS ACCREDITED FOR 15CME HOURS Licensed by: Sponsored by: (+966) 11 462 2515 Ext.

More information

A JOHNS HOPKINS SINGAPORE ANNUAL RESEARCH REPORT 2015

A JOHNS HOPKINS SINGAPORE ANNUAL RESEARCH REPORT 2015 A JOHNS HOPKINS SINGAPORE ANNUAL RESEARCH REPORT 2015 15 years of excellence in patient care, research, and education The Promise of Medicine: The research team at Johns Hopkins Singapore provides unparalleled

More information

Docetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.

Docetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled

More information

The Clinical Research E-News

The Clinical Research E-News The Clinical Research E-News Volume 6: ISSUE 5: May 14, 2014 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials Actively

More information

UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma

UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Supported by a grant from Supported by a grant from UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Jonathan W.

More information